Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
neurotrophin-3 + chitosan
- Development stage
- Unknown
- Lead developer
- Huashan Hospital
- Modality
- Hydrogel Systems → Drug Delivery Systems, Recombinant Proteins and Enzymes
- Administration
- Intracerebral
01
Overview
Neurotrophin-3 + chitosan is an experimental regenerative combination therapy developed by Huashan Hospital, Fudan University, for the treatment of hypertensive cerebral hemorrhage (ICH). The therapy utilizes a chitosan-based hydrogel that serves as a biocompatible and biodegradable scaffold, providing a structural matrix for tissue repair while ensuring the sustained release of neurotrophin-3 (NT-3) directly at the site of brain injury. NT-3 is a neurotrophic factor that binds to the TrkC receptor, promoting the survival, differentiation, and axonal growth of neurons. By delivering NT-3 into the hematoma cavity following surgical evacuation, the treatment aims to facilitate neural circuit reconstruction and improve motor and neurological recovery in patients suffering from the long-term effects of ICH.
- Other names
- Neurotrophin-3-loaded chitosan hydrogelNeurotrophin3-loaded chitosan hydrogelNeurotrophin 3-loaded chitosan hydrogelNT-3-chitosan scaffoldNT3-chitosan scaffoldNT 3-chitosan scaffold
02
Targets
NTRK3 (Tropomyosin receptor kinase C)TYRP1 (Tyrosinase-related protein 1)
Beyond the preview
Go deeper on neurotrophin-3 + chitosan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on neurotrophin-3 + chitosan.